CHDI
Listed here are over 1,045 publications that describe some of the research funded (in whole or in part) by CHDI Foundation. You can also view just the subset of publications that have CHDI staff as authors.
Publication Search
Title
Journal
Sun Z, Li Y, Ghosh S, Cheng Y, Mohan A, Sampaio C, Hu J
A data-driven method for generating robust symptom onset indicators in Huntington's disease registry data
Wijeratne PA, Young AL, Oxtoby NP, Marinescu RV, Firth NC, Johnson EB, Mohan A, Sampaio C, Scahill RI, Tabrizi SJ, Alexander DC
An image-based model of brain volume biomarker changes in Huntington's disease
Ann Clin Transl Neurol
April 2, 2018
5 (5) :570-582
5 (5) :570-582
PMID: 29761120
PMCID: PMC5945962
DOI: 10.1002/acn3.558
Reiner A, Deng YP
Disrupted striatal neuron inputs and outputs in Huntington's disease
CNS Neurosci Ther
April 2, 2018
24 (4) :250-280
24 (4) :250-280
PMID: 29582587
PMCID: PMC5875736
DOI: 10.1111/cns.12844
Carlozzi NE, Hahn EA, Goodnight SM, Kratz AL, Paulsen JS, Stout JC, Frank S, Miner JA, Cella D, Gershon RC, Schilling SG, Ready RE
Patient-reported outcome measures in Huntington disease: Quality of life in neurological disorders (Neuro-QoL) social functioning measures
Psychol Assess
April 2, 2018
30 (4) :450-458
30 (4) :450-458
PMID: 28557480
PMCID: PMC5708162
DOI: 10.1037/pas0000479
Lai JS, Goodnight S, Downing NR, Ready RE, Paulsen JS, Kratz AL, Stout JC, McCormack MK, Cella D, Ross C, Russell J, Carlozzi NE
Evaluating cognition in individuals with Huntington disease: Neuro-QoL cognitive functioning measures
Baake V, Coppen EM, van Duijn E, Dumas EM, van den Bogaard SJA, Scahill RI, Johnson H, Leavitt B, Durr A, Tabrizi SJ, Craufurd D, Roos RAC, Track-HD investigators
Apathy and atrophy of subcortical brain structures in Huntington's disease: A two-year follow-up study
Ament SA, Pearl JR, Cantle JP, Bragg RM, Skene PJ, Coffey SR, Bergey DE, Wheeler VC, MacDonald ME, Baliga NS, Rosinski J, Hood LE, Carroll JB, Price ND
Transcriptional regulatory networks underlying gene expression changes in Huntington's disease
Mestre TA, Carlozzi NE, Ho AK, Burgunder JM, Walker F, Davis AM, Busse M, Quinn L, Rodrigues FB, Sampaio C, Goetz CG, Cubo E, Martinez-Martin P, Stebbins GT, Members of the MDS Committee on Rating Scales Development|
Quality of life in Huntington's disease: Critique and recommendations for measures assessing patient health-related quality of life and caregiver quality of life
Bresciani A, Spiezia MC, Boggio R, Cariulo C, Nordheim A, Altobelli R, Kuhlbrodt K, Dominguez C, Munoz-Sanjuan I, Wityak J, Fodale V, Marchionini DM, Weiss A
Quantifying autophagy using novel LC3B and p62 TR-FRET assays
Ouk K, Aungier J, Cuesta M, Morton AJ
Chronic paroxetine treatment prevents disruption of methamphetamine-sensitive circadian oscillator in a transgenic mouse model of Huntington's disease
Minkova L, Gregory S, Scahill RI, Abdulkadir A, Kaller CP, Peter J, Long JD, Stout JC, Reilmann R, Roos RA, Durr A, Leavitt BR, Tabrizi SJ, Klöppel S, TRACK-HD Investigators
Cross-sectional and longitudinal voxel-based grey matter asymmetries in Huntington's disease
Espinoza FA, Turner JA, Vergara VM, Miller RL, Mennigen E, Liu J, Misiura MB, Ciarochi J, Johnson HJ, Long JD, Bockholt HJ, Magnota VA, Paulsen JS, Calhoun VD
Whole-brain connectivity in a large study of Huntington's disease gene mutation carriers and healthy controls
Lee CYD, Daggett A, Gu X, Jiang LL, Langfelder P, Li X, Wang N, Zhao Y, Park CS, Cooper Y, Ferando I, Mody I, Coppola G, Xu H, Yang XW
Elevated TREM2 gene dosage reprograms microglia responsivity and ameliorates pathological phenotypes in Alzheimer's disease models
Guo Q, Bin Huang, Cheng J, Seefelder M, Engler T, Pfeifer G, Oeckl P, Otto M, Moser F, Maurer M, Pautsch A, Baumeister W, Fernández-Busnadiego R, Kochanek S
The cryo-electron microscopy structure of huntingtin
Odish OFF, Reijntjes RHAM, van den Bogaard SJA, Roos RAC, Leemans A
Progressive microstructural changes of the occipital cortex in Huntington's disease
Kielar C, Morton AJ
Early neurodegeneration in R6/2 mice carrying the Huntington's disease mutation with a super-expanded CAG repeat, despite normal lifespan
Kovalenko M, Milnerwood A, Giordano J, St Claire J, Guide JR, Stromberg M, Gillis T, Sapp E, DiFiglia M, MacDonald ME, Carroll JB, Lee JM, Tappan S, Raymond L, Wheeler VC
HttQ111/+ Huntington's disease knock-in mice exhibit brain region-specific morphological changes and synaptic dysfunction
Pfister EL, DiNardo N, Mondo E, Borel F, Conroy F, Fraser C, Gernoux G, Han X, Hu D, Johnson E, Kennington L, Liu P, Reid SJ, Sapp E, Vodicka P, Kuchel T, Morton AJ, Howland D, Moser R, Sena-Esteves M, Gao G, Mueller C, DiFiglia M, Aronin N
Artificial miRNAs reduce Human Mutant Huntingtin throughout the striatum in a transgenic sheep model of Huntington's disease
Veldman MB, Yang XW
Molecular insights into cortico-striatal miscommunications in Huntington's disease
Davis MI, Crittenden JR, Feng AY, Kupferschmidt DA, Naydenov A, Stella N, Graybiel AM, Lovinger DM
The cannabinoid-1 receptor is abundantly expressed in striatal striosomes and striosome-dendron bouquets of the substantia nigra
Rebec GV
Corticostriatal network dysfunction in huntington's disease: Deficits in neural processing, glutamate transport, and ascorbate release
Sampaio C, Levey J, Klitzman R
Predictive testing and clinical trials in Huntington's disease: An ethical analysis
Mov Disord
February 20, 2018
33 (2) :243-247
33 (2) :243-247
PMID: 29205501
PMCID: PMC5854324
DOI: 10.1002/mds.27247
Mestre TA, Bachoud-Lévi AC, Marinus J, Stout JC, Paulsen JS, Como P, Duff K, Sampaio C, Goetz CG, Cubo E, Stebbins GT, Martinez-Martin P, Members of the MDS Committee on Rating Scales Development
Rating scales for cognition in Huntington's disease: Critique and recommendations
Hassler MR, Turanov AA, Alterman JF, Haraszti RA, Coles AH, Osborn MF, Echeverria D, Nikan M, Salomon WE, Roux L, Godinho BMDC, Davis SM, Morrissey DV, Zamore PD, Karumanchi SA, Moore MJ, Aronin N, Khvorova A
Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo
Harrison DJ Roberton VH Vinh NN Brooks SP Dunnett SB Rosser AE
The effect of tissue preparation and donor age on striatal graft morphology in the mouse
Arnerić SP, Kern VD, Stephenson DT
Regulatory-accepted drug development tools are needed to accelerate innovative CNS disease treatments
Ruzo A, Croft GF, Metzger JJ, Galgoczi S, Gerber LJ, Pellegrini C, Wang H Jr, Fenner M, Tse S, Marks A, Nchako C, Brivanlou AH
Chromosomal instability during neurogenesis in Huntington's disease
Johnson EB, Byrne LM, Gregory S, Rodrigues FB, Blennow K, Durr A, Leavitt BR, Roos RA, Zetterberg H, Tabrizi SJ, Scahill RI, Wild EJ, TRACK-HD Study Group
Neurofilament light protein in blood predicts regional atrophy in Huntington disease
Reed ER, Latourelle JC, Bockholt JH, Bregu J, Smock J, Paulsen JS, Myers RH, PREDICT-HD CSF ancillary study investigators
MicroRNAs in CSF as prodromal biomarkers for Huntington disease in the PREDICT-HD study
Sbodio JI, Snyder SH, Paul BD
Golgi stress response reprograms cysteine metabolism to confer cytoprotection in Huntington's disease
Casula EP, Mayer IMS, Desikan M, Tabrizi SJ, Rothwell JC, Orth M
Motor cortex synchronization influences the rhythm of motor performance in premanifest Huntington's disease
Sepers MD, Smith-Dijak A, LeDue J, Kolodziejczyk K, Mackie K, Raymond LA
Endocannabinoid-specific impairment in synaptic plasticity in striatum of Huntington's disease mouse model
Langfelder P, Gao F, Wang N, Howland D, Kwak S, Vogt TF, Aaronson JS, Rosinski J, Coppola G, Horvath S, Yang XW
MicroRNA signatures of endogenous Huntingtin CAG repeat expansion in mice
Carlozzi NE, Hahn EA, Frank SA, Perlmutter JS, Downing ND, McCormack MK, Barton S, Nance MA, Schilling SG, HDQLIFE Site Investigators and Coordinators
A new measure for end of life planning, preparation, and preferences in Huntington disease: HDQLIFE end of life planning
Conforti P, Besusso D, Bocchi VD, Faedo A, Cesana E, Rossetti G, Ranzani V, Svendsen CN, Thompson LM, Toselli M, Biella G, Pagani M, Cattaneo E
Faulty neuronal determination and cell polarization are reverted by modulating HD early phenotypes
Proc Natl Acad Sci USA
January 8, 2018
115 (4) :E762-E771
115 (4) :E762-E771
PMID: 29311338
Mestre TA, Forjaz MJ, Mahlknecht P, Cardoso F, Ferreira JJ, Reilmann R, Sampaio C, Goetz CG, Cubo E, Martinez-Martin P, Stebbins GT, Members of the Movement Disorder Society Committee on Rating Scales Development
Rating scales for motor symptoms and signs in Huntington's disease: Critique and recommendations
Mov Disord Clin Pract
January 3, 2018
5 (2) :111-117
5 (2) :111-117
PMID: 30363393
PMCID: 6174417
DOI: 10.1002/mdc3.12571
Wang HB, Loh DH, Whittaker DS, Cutler T, Howland D, Colwell CS
Time-restricted feeding improves circadian dysfunction as well as motor symptoms in the Q175 mouse model of Huntington's disease
Al-Ramahi I, Panapakkam Giridharan SS, Chen YC, Patnaik S, Safren N, Hasegawa J, de Haro M, Wagner Gee AK, Titus SA, Jeong H, Clarke J, Krainc D, Zheng W, Irvine RF, Barmada S, Ferrer M, Southall N, Weisman LS, Botas J, Marugan JJ
Inhibition of PIP4Kγ ameliorates the pathological effects of mutant huntingtin protein
Hensman Moss DJ, Robertson N, Farmer R, Scahill RI, Haider S, Tessari MA, Flynn G, Fischer DF, Wild EJ, Macdonald D, Tabrizi SJ
Quantification of huntingtin protein species in Huntington's disease patient leukocytes using optimised electrochemiluminescence immunoassays
Schobel SA, Palermo G, Auinger P, Long JD, Ma S, Khwaja OS, Trundell D, Cudkowicz M, Hersch S, Sampaio C, Dorsey ER, Leavitt BR, Kieburtz KD, Sevigny JJ, Langbehn DR, Tabrizi SJ, TRACK-HD, COHORT, CARE-HD, and 2CARE Huntington Study Group Investigators
Motor, cognitive, and functional declines contribute to a single progressive factor in early HD